Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Pieris Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Pieris Pharmaceuticals şirketinin toplam hissedar öz sermayesi $22.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $29.5M ve $7.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$19.08m
Eşitlik	US$21.96m
Toplam yükümlülükler	US$7.53m
Toplam varlıklar	US$29.50m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PI60 'nin kısa vadeli varlıkları ( $29.5M ) kısa vadeli yükümlülüklerini ( $7.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: PI60 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PI60 borçsuzdur.

Borcun Azaltılması: PI60 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PI60 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: PI60 un, serbest nakit akışı her yıl % 22.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Pieris Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Recent updates

Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. Announce Definitive Merger Agreement

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.13 loss in 3Q 2022)

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Insufficient new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.24 loss in 3Q 2021)

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.25 loss in 2Q 2021)

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.074 loss in 1Q 2021)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: €1.99

New 90-day high: €2.47

Third quarter 2020 earnings released: US$0.26 loss per share

Revenue misses expectations

New 90-day low: €1.94

Earnings released

New 90-day low - €2.16

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin